Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Achieve Life Sciences Inc
(NQ:
ACHV
)
4.510
+0.110 (+2.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Achieve Life Sciences Inc
< Previous
1
2
Next >
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
December 15, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
March 29, 2023
Topline Data Expected in 2Q 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
December 12, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Achieve Life Sciences Inc. (NASDAQ: ACHV) Climbs to New 52-Week High
April 26, 2023
Via
Investor Brand Network
Achieve Life Sciences Announces Refresh to Board of Directors
March 30, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
March 08, 2023
Topline Data Expected in 2Q 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
March 03, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
March 02, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
February 07, 2023
Topline Data Expected in 2Q 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Granting of New Hire Inducement Award
March 17, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
February 02, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Granting of New Hire Inducement Award
January 27, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
January 09, 2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
December 21, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences Announces Private Placement of $18.9 Million
November 15, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
November 08, 2022
Phase 2 ORCA-V1 Data Expected in 1H2023
From
Achieve Life Sciences
Via
GlobeNewswire
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
October 31, 2022
From
Achieve Life Sciences
Via
GlobeNewswire
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
January 28, 2022
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public...
From
MicroCap Rodeo
Via
AccessWire
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
May 16, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public...
From
MicroCap Rodeo
Via
AccessWire
Achieve Life Sciences to Participate in Upcoming Investor Conferences
September 15, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
September 14, 2021
SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Achieve Life Sciences to Participate in Two Upcoming Investor Conferences
September 09, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
August 13, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
August 11, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
COVID-19
Death
Intellectual Property
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
August 11, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Product Safety
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
August 03, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
July 22, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Product Safety
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
June 29, 2021
ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE /...
From
Achieve Life Sciences, Inc.
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.